AKBA
Price
$1.88
Change
-$0.05 (-2.59%)
Updated
Apr 3, 04:59 PM (EDT)
Capitalization
504.18M
38 days until earnings call
MIST
Price
$0.75
Change
-$0.05 (-6.25%)
Updated
Apr 3, 04:59 PM (EDT)
Capitalization
40.02M
45 days until earnings call
Ad is loading...

AKBA vs MIST

Header iconAKBA vs MIST Comparison
Open Charts AKBA vs MISTBanner chart's image
Akebia Therapeutics
Price$1.88
Change-$0.05 (-2.59%)
Volume$22.85K
Capitalization504.18M
Milestone Pharmaceuticals
Price$0.75
Change-$0.05 (-6.25%)
Volume$9.82K
Capitalization40.02M
AKBA vs MIST Comparison Chart
Loading...
AKBA
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
MIST
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
View a ticker or compare two or three
VS
AKBA vs. MIST commentary
Apr 04, 2025

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is AKBA is a Hold and MIST is a Hold.

Ad is loading...
COMPARISON
Comparison
Apr 04, 2025
Stock price -- (AKBA: $1.88 vs. MIST: $0.75)
Brand notoriety: AKBA and MIST are both not notable
Both companies represent the Biotechnology industry
Current volume relative to the 65-day Moving Average: AKBA: 82% vs. MIST: 99%
Market capitalization -- AKBA: $504.18M vs. MIST: $40.02M
AKBA [@Biotechnology] is valued at $504.18M. MIST’s [@Biotechnology] market capitalization is $40.02M. The market cap for tickers in the [@Biotechnology] industry ranges from $299.64B to $0. The average market capitalization across the [@Biotechnology] industry is $2.21B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

AKBA’s FA Score shows that 0 FA rating(s) are green whileMIST’s FA Score has 0 green FA rating(s).

  • AKBA’s FA Score: 0 green, 5 red.
  • MIST’s FA Score: 0 green, 5 red.
According to our system of comparison, AKBA is a better buy in the long-term than MIST.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

AKBA’s TA Score shows that 2 TA indicator(s) are bullish while MIST’s TA Score has 4 bullish TA indicator(s).

  • AKBA’s TA Score: 2 bullish, 8 bearish.
  • MIST’s TA Score: 4 bullish, 5 bearish.
According to our system of comparison, MIST is a better buy in the short-term than AKBA.

Price Growth

AKBA (@Biotechnology) experienced а -2.59% price change this week, while MIST (@Biotechnology) price change was -66.67% for the same time period.

The average weekly price growth across all stocks in the @Biotechnology industry was -8.91%. For the same industry, the average monthly price growth was -11.19%, and the average quarterly price growth was -14.86%.

Reported Earning Dates

AKBA is expected to report earnings on May 12, 2025.

MIST is expected to report earnings on May 19, 2025.

Industries' Descriptions

@Biotechnology (-8.91% weekly)

Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.

SUMMARIES
Loading...
FUNDAMENTALS
Fundamentals
AKBA($504M) has a higher market cap than MIST($40M). AKBA YTD gains are higher at: 1.579 vs. MIST (-68.220). AKBA has higher annual earnings (EBITDA): -13.72M vs. MIST (-37.83M). MIST has more cash in the bank: 69.7M vs. AKBA (51.9M). AKBA has less debt than MIST: AKBA (47.6M) vs MIST (54.8M). AKBA has higher revenues than MIST: AKBA (160M) vs MIST (0).
AKBAMISTAKBA / MIST
Capitalization504M40M1,260%
EBITDA-13.72M-37.83M36%
Gain YTD1.579-68.220-2%
P/E RatioN/AN/A-
Revenue160M0-
Total Cash51.9M69.7M74%
Total Debt47.6M54.8M87%
FUNDAMENTALS RATINGS
AKBA vs MIST: Fundamental Ratings
AKBA
MIST
OUTLOOK RATING
1..100
7770
VALUATION
overvalued / fair valued / undervalued
1..100
69
Overvalued
56
Fair valued
PROFIT vs RISK RATING
1..100
100100
SMR RATING
1..100
100100
PRICE GROWTH RATING
1..100
4297
P/E GROWTH RATING
1..100
100100
SEASONALITY SCORE
1..100
5065

Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.

MIST's Valuation (56) in the Pharmaceuticals Major industry is in the same range as AKBA (69) in the Biotechnology industry. This means that MIST’s stock grew similarly to AKBA’s over the last 12 months.

MIST's Profit vs Risk Rating (100) in the Pharmaceuticals Major industry is in the same range as AKBA (100) in the Biotechnology industry. This means that MIST’s stock grew similarly to AKBA’s over the last 12 months.

MIST's SMR Rating (100) in the Pharmaceuticals Major industry is in the same range as AKBA (100) in the Biotechnology industry. This means that MIST’s stock grew similarly to AKBA’s over the last 12 months.

AKBA's Price Growth Rating (42) in the Biotechnology industry is somewhat better than the same rating for MIST (97) in the Pharmaceuticals Major industry. This means that AKBA’s stock grew somewhat faster than MIST’s over the last 12 months.

AKBA's P/E Growth Rating (100) in the Biotechnology industry is in the same range as MIST (100) in the Pharmaceuticals Major industry. This means that AKBA’s stock grew similarly to MIST’s over the last 12 months.

TECHNICAL ANALYSIS
Technical Analysis
AKBAMIST
RSI
ODDS (%)
Bearish Trend 2 days ago
86%
Bullish Trend 2 days ago
90%
Stochastic
ODDS (%)
Bullish Trend 2 days ago
84%
Bullish Trend 2 days ago
90%
Momentum
ODDS (%)
Bearish Trend 2 days ago
81%
Bearish Trend 2 days ago
85%
MACD
ODDS (%)
Bearish Trend 2 days ago
90%
Bearish Trend 2 days ago
81%
TrendWeek
ODDS (%)
Bullish Trend 2 days ago
84%
Bearish Trend 2 days ago
81%
TrendMonth
ODDS (%)
Bullish Trend 2 days ago
84%
Bearish Trend 2 days ago
81%
Advances
ODDS (%)
Bullish Trend 16 days ago
85%
Bullish Trend 8 days ago
83%
Declines
ODDS (%)
Bearish Trend 9 days ago
85%
Bearish Trend 3 days ago
83%
BollingerBands
ODDS (%)
Bearish Trend 2 days ago
86%
Bullish Trend 2 days ago
84%
Aroon
ODDS (%)
Bearish Trend 2 days ago
84%
N/A
View a ticker or compare two or three
Ad is loading...
AKBA
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
MIST
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
MFs / NAMEPrice $Chg $Chg %
JRSIX11.450.07
+0.62%
JH Adaptive Risk Mgd U.S. Eq I
WLGRX31.17N/A
N/A
Macquarie Large Cap Growth Fund R
FIQVX33.15N/A
N/A
Fidelity Advisor Convertible Secs Z
FVRMX23.47N/A
N/A
Franklin Mutual Small-Mid Cap Val Adv
FSUMX13.27N/A
N/A
Fidelity Series Sustainable U.S. Market

AKBA and

Correlation & Price change

A.I.dvisor indicates that over the last year, AKBA has been loosely correlated with ABOS. These tickers have moved in lockstep 43% of the time. This A.I.-generated data suggests there is some statistical probability that if AKBA jumps, then ABOS could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To AKBA
1D Price
Change %
AKBA100%
+1.05%
ABOS - AKBA
43%
Loosely correlated
+0.47%
KOD - AKBA
41%
Loosely correlated
+4.30%
ADAP - AKBA
38%
Loosely correlated
+22.00%
OCGN - AKBA
38%
Loosely correlated
+6.46%
ABCL - AKBA
37%
Loosely correlated
+6.22%
More

MIST and

Correlation & Price change

A.I.dvisor tells us that MIST and AKBA have been poorly correlated (+33% of the time) for the last year. This A.I.-generated data suggests there is low statistical probability that MIST and AKBA's prices will move in lockstep.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To MIST
1D Price
Change %
MIST100%
-6.61%
AKBA - MIST
33%
Poorly correlated
-2.59%
GYRE - MIST
29%
Poorly correlated
-4.37%
PRAX - MIST
29%
Poorly correlated
-10.08%
OSRH - MIST
29%
Poorly correlated
+68.03%
ADAP - MIST
28%
Poorly correlated
+7.74%
More